From January 1992 to December 1992,32 patients with jung cancer which were centrally located and considered to be non-operable were treated by bronchial artery chemoembolization.
Objective To evaluate the value of autofluorescence bronchoscope (AFB) in airway examination in central type lung cancer. Methods From Sep 2009 to Mar 2010,29 patients (23 men,6 women,median age 62. 2 years,range from...Objective To evaluate the value of autofluorescence bronchoscope (AFB) in airway examination in central type lung cancer. Methods From Sep 2009 to Mar 2010,29 patients (23 men,6 women,median age 62. 2 years,range from 34 to 81 years) underwent AFB procedure. There were 3 lesions located at trachea,1 at展开更多
BACKGROUND Central nervous system(CNS) metastases are a catastrophic complication of nonsmall cell lung cancer(NSCLC), including brain and leptomeningeal carcinomatosis, and are always accompanied by a poor prognosis....BACKGROUND Central nervous system(CNS) metastases are a catastrophic complication of nonsmall cell lung cancer(NSCLC), including brain and leptomeningeal carcinomatosis, and are always accompanied by a poor prognosis. Despite the continuous development of existing treatments, the therapy of CNS metastases remains challenging.CASE SUMMARY We report a patient who was definitively diagnosed with brain and leptomeningeal metastases from NSCLC with a targeted mutation in epidermal growth factor receptor(EGFR). A standard dosage of icotinib(125 mg three times daily) was implemented but ineffective. CNS lesions developed despite stable systemic control, so pulsatile icotinib(1125 mg every 3 d) was administered. This new strategy for administration has lasted 25 mo so far, and resulted in complete remission of neurological symptoms, almost vanished lesions, and longer survival with no notable side effects.CONCLUSION This is the first successful example of pulsatile icotinib for treating isolated CNS progression from EGFR mutation-positive NSCLC, providing a new alternative for the local treatment of CNS metastases.展开更多
Background: As the prognosis of lung cancer (LC) patients improves, subcutaneously implanted central venous access device ports (CV-ports) have frequently been used for continuing chemotherapy (CC) or palliative care ...Background: As the prognosis of lung cancer (LC) patients improves, subcutaneously implanted central venous access device ports (CV-ports) have frequently been used for continuing chemotherapy (CC) or palliative care (PC). In this study, we examined the clinical course of LC patients with subcutaneously implanted CV-ports from the time of receiving chemotherapy to the endpoint of cancer. Materials and Methods: We retrospectively reviewed the clinical data and treatment history of LC patients with subcutaneously implanted CV-ports between June 2008 and November 2013 using clinical records and a pharmacy database. Results: Of the 132 LC patients with subcutaneously implanted CV-ports, 79 (59.8%) had CV-ports for CC (the CC group) and 53 (40.2%) had CV-ports for PC (the PC group). After CV-port implantation, LC patients in the CC group received a median of two regimens with a median of 6 cycles. The median survival time of patients in the CC and PC groups was 457 and 44 days, respectively. In the CC group, the median survival time of small cell and non-small cell LC patients was 342 (95% confidence interval, 235 - 627) and 563 (95% confidence interval, 368 - 728) days, respectively. Nine patients (6.8%) had their CV-ports removed due to complications. Forty (30.3%) of the 132 enrolled patients were referred for at-home PC. The at-home death rate observed among these 40 patients was 30.0% (N = 12). Conclusion: CV-ports may contribute to seamless oncological care.展开更多
Predicting the stages of cancer accurately is crucial for effective treatment planning. In this study, we aimed to develop a model using gene expression data and XGBoost (eXtreme Gradient Boosting) that include clinic...Predicting the stages of cancer accurately is crucial for effective treatment planning. In this study, we aimed to develop a model using gene expression data and XGBoost (eXtreme Gradient Boosting) that include clinical and demographic variables to predict specific lung cancer stages in patients. By conducting the feature selection using the Wilcoxon Rank Test, we picked the most impactful genes associated with lung cancer stage prediction. Our model achieved an overall accuracy of 82% in classifying lung cancer stages according to patients’ gene expression data. These findings demonstrate the potential of gene expression analysis and machine learning techniques in improving the accuracy of lung cancer stage prediction, aiding in personalized treatment decisions.展开更多
Background: The goal of this study was to retrospectively compare the initial success rate and rate of intraoperative and late complications between the femoral and subclavian vein approaches used to implant venous ac...Background: The goal of this study was to retrospectively compare the initial success rate and rate of intraoperative and late complications between the femoral and subclavian vein approaches used to implant venous access ports without guidance in lung cancer patients. Methods: We conducted a retrospective review of total 163 lung cancer patients who underwent implantations of a central venous access port for chemotherapy. 95 patients received the ports by the femoral vein blind-puncture technique and 68patients had the port implanted via the subclavian vein blind-puncture technique. The initial success rate of port implantation and the frequency of occurrence of complications were calculated. Results: The primary success rate of venous port implantation was 93.7% for femoral approach and 88.2% for the subclavian approach respectively (p < 0.05). Intraoperative complications developed in two patients (2.1%) in the femoral approach group and in five patients (7.4%) in the subclavian approach group. Although a higher intraoperative complication ratio for the subclavian approach was encountered compared to that for the femoral vein approach, there was no statistically significant difference (p = 0.103). Nor was there any statistically significant difference in terms of the occurrence of late complications. Conclusions: Venous access port implantation via the femoral vein approach is safe, and its success rate is very high, with the equal complication rates comparable to the subclavian approach. This approach avoids many of the intraoperative complications. Thus, the femoral vein approach for implanting a venous access port in lung cancer patients should be considered a valid, and safe technique.展开更多
目的本研究旨在探讨融入胸部CT测量法在预测肺癌患者耐高压型经外周置入中心静脉导管(peripherally inserted central catheter,PICC)最佳尖端位置中的应用效果。方法选取来自2023年8—12月在陕西省某三甲医院胸外科行PICC置管的205例...目的本研究旨在探讨融入胸部CT测量法在预测肺癌患者耐高压型经外周置入中心静脉导管(peripherally inserted central catheter,PICC)最佳尖端位置中的应用效果。方法选取来自2023年8—12月在陕西省某三甲医院胸外科行PICC置管的205例肺癌患者。采用计算机随机法将患者随机分为对照组(传统的体表横“L”测量法)102例和观察组(融入胸部CT测量法)103例。主要评价指标为PICC导管最佳尖端位置的准确率,次要评价指标为置管后30 d内并发症的发生率。结果2组PICC最佳尖端位置的准确率分别为86.41%和30.39%,观察组高于对照组(OR=14.560,95%CI:7.202~29.437,P<0.001)。调整性别、年龄和BMI的影响后,2组间最佳尖端位置的准确率差异仍具有统计学意义(OR=16.383,95%CI:7.824~34.308,P<0.001)。观察组30 d内导管滑脱的风险低于对照组(1.94%vs 11.76%,OR=0.154,95%CI:0.033~0.718,P=0.017),2组间机械性静脉炎的发生率差异无统计学意义(P>0.05)。结论融入胸部CT测量法可提高PICC最佳尖端位置准确率,降低导管滑脱的发生率。本研究作为一项护理新技术,研究结果可推广到肺癌等其他需要常规行胸部CT检查的患者领域,在不额外增加辐射和费用的前提下,可提高PICC测量的准确性。展开更多
文摘From January 1992 to December 1992,32 patients with jung cancer which were centrally located and considered to be non-operable were treated by bronchial artery chemoembolization.
文摘Objective To evaluate the value of autofluorescence bronchoscope (AFB) in airway examination in central type lung cancer. Methods From Sep 2009 to Mar 2010,29 patients (23 men,6 women,median age 62. 2 years,range from 34 to 81 years) underwent AFB procedure. There were 3 lesions located at trachea,1 at
基金Supported by the Key Project of Nanjing Health Bureau,No.ZKX16031the Healthcare Project of Nanjing Science and Technology Committee,No.201715020+2 种基金the Medical Key Science and Technology Development Project of Nanjing,No.ZKX18014the Cadre Health Care Project of Jiangsu Province,No.BJ18006the Cancer Research Funding of CSCO-Hausen,No.Y-HS2019-5
文摘BACKGROUND Central nervous system(CNS) metastases are a catastrophic complication of nonsmall cell lung cancer(NSCLC), including brain and leptomeningeal carcinomatosis, and are always accompanied by a poor prognosis. Despite the continuous development of existing treatments, the therapy of CNS metastases remains challenging.CASE SUMMARY We report a patient who was definitively diagnosed with brain and leptomeningeal metastases from NSCLC with a targeted mutation in epidermal growth factor receptor(EGFR). A standard dosage of icotinib(125 mg three times daily) was implemented but ineffective. CNS lesions developed despite stable systemic control, so pulsatile icotinib(1125 mg every 3 d) was administered. This new strategy for administration has lasted 25 mo so far, and resulted in complete remission of neurological symptoms, almost vanished lesions, and longer survival with no notable side effects.CONCLUSION This is the first successful example of pulsatile icotinib for treating isolated CNS progression from EGFR mutation-positive NSCLC, providing a new alternative for the local treatment of CNS metastases.
文摘Background: As the prognosis of lung cancer (LC) patients improves, subcutaneously implanted central venous access device ports (CV-ports) have frequently been used for continuing chemotherapy (CC) or palliative care (PC). In this study, we examined the clinical course of LC patients with subcutaneously implanted CV-ports from the time of receiving chemotherapy to the endpoint of cancer. Materials and Methods: We retrospectively reviewed the clinical data and treatment history of LC patients with subcutaneously implanted CV-ports between June 2008 and November 2013 using clinical records and a pharmacy database. Results: Of the 132 LC patients with subcutaneously implanted CV-ports, 79 (59.8%) had CV-ports for CC (the CC group) and 53 (40.2%) had CV-ports for PC (the PC group). After CV-port implantation, LC patients in the CC group received a median of two regimens with a median of 6 cycles. The median survival time of patients in the CC and PC groups was 457 and 44 days, respectively. In the CC group, the median survival time of small cell and non-small cell LC patients was 342 (95% confidence interval, 235 - 627) and 563 (95% confidence interval, 368 - 728) days, respectively. Nine patients (6.8%) had their CV-ports removed due to complications. Forty (30.3%) of the 132 enrolled patients were referred for at-home PC. The at-home death rate observed among these 40 patients was 30.0% (N = 12). Conclusion: CV-ports may contribute to seamless oncological care.
文摘Predicting the stages of cancer accurately is crucial for effective treatment planning. In this study, we aimed to develop a model using gene expression data and XGBoost (eXtreme Gradient Boosting) that include clinical and demographic variables to predict specific lung cancer stages in patients. By conducting the feature selection using the Wilcoxon Rank Test, we picked the most impactful genes associated with lung cancer stage prediction. Our model achieved an overall accuracy of 82% in classifying lung cancer stages according to patients’ gene expression data. These findings demonstrate the potential of gene expression analysis and machine learning techniques in improving the accuracy of lung cancer stage prediction, aiding in personalized treatment decisions.
文摘Background: The goal of this study was to retrospectively compare the initial success rate and rate of intraoperative and late complications between the femoral and subclavian vein approaches used to implant venous access ports without guidance in lung cancer patients. Methods: We conducted a retrospective review of total 163 lung cancer patients who underwent implantations of a central venous access port for chemotherapy. 95 patients received the ports by the femoral vein blind-puncture technique and 68patients had the port implanted via the subclavian vein blind-puncture technique. The initial success rate of port implantation and the frequency of occurrence of complications were calculated. Results: The primary success rate of venous port implantation was 93.7% for femoral approach and 88.2% for the subclavian approach respectively (p < 0.05). Intraoperative complications developed in two patients (2.1%) in the femoral approach group and in five patients (7.4%) in the subclavian approach group. Although a higher intraoperative complication ratio for the subclavian approach was encountered compared to that for the femoral vein approach, there was no statistically significant difference (p = 0.103). Nor was there any statistically significant difference in terms of the occurrence of late complications. Conclusions: Venous access port implantation via the femoral vein approach is safe, and its success rate is very high, with the equal complication rates comparable to the subclavian approach. This approach avoids many of the intraoperative complications. Thus, the femoral vein approach for implanting a venous access port in lung cancer patients should be considered a valid, and safe technique.
